This company listing is no longer active
Biotage (PQX1) Stock Overview
Provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
PQX1 passed our risk checks.
PQX1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Biotage AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 12.47 |
| 52 Week High | SEK 17.33 |
| 52 Week Low | SEK 7.51 |
| Beta | 0.85 |
| 1 Month Change | -0.95% |
| 3 Month Change | -5.53% |
| 1 Year Change | -21.62% |
| 3 Year Change | -39.93% |
| 5 Year Change | -18.39% |
| Change since IPO | 1,658.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| PQX1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -5.2% | -4.5% |
| 1Y | -21.6% | -23.3% | -4.8% |
Return vs Industry: PQX1 underperformed the German Life Sciences industry which returned -14.8% over the past year.
Return vs Market: PQX1 underperformed the German Market which returned 18.3% over the past year.
Price Volatility
| PQX1 volatility | |
|---|---|
| PQX1 Average Weekly Movement | 3.7% |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.1% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: PQX1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PQX1's weekly volatility has decreased from 9% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 622 | Frederic Vanderhaegen | www.biotage.com |
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal and supported scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables, systems, and workflows; biomolecule purification solutions, including antibody, plasmid, AAV, and tagged proteins purification; automation systems; and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
Biotage AB (publ) Fundamentals Summary
| PQX1 fundamental statistics | |
|---|---|
| Market cap | €1.03b |
| Earnings (TTM) | €22.81m |
| Revenue (TTM) | €175.44m |
Is PQX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQX1 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.96b |
| Cost of Revenue | SEK 733.00m |
| Gross Profit | SEK 1.23b |
| Other Expenses | SEK 973.00m |
| Earnings | SEK 255.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 06, 2025
| Earnings per share (EPS) | 3.19 |
| Gross Margin | 62.62% |
| Net Profit Margin | 13.00% |
| Debt/Equity Ratio | 3.9% |
How did PQX1 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/23 20:57 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotage AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Odysseas Manesiotis | Berenberg |
| Marcus Bellander | Carnegie Investment Bank AB |